Chip Wilson Comments on Leadership Change at lululemon
Get Alerts LULU Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.8%
Revenue Growth %: -11.2%
Join SI Premium – FREE
Founder of lululemon and Largest Active Shareholder Deeply Concerned Board Has Again Failed at Succession Planning
Will Continue to Actively Engage lululemon to Unlock Value for All Shareholders
"As I have communicated to members of the Company publicly and privately, lululemon needs revitalization and an infusion of new skills to get back to being a product-first company that creates real, long-term shareholder value. After overseeing years of poor decisions erode the brand and destroy shareholder value, it is clear to me that only under my increasing pressure has the lululemon Board of Directors (the "Board") finally started to listen," said Dennis J. "Chip" Wilson, Founder of lululemon. "As one of the largest active shareholders of lululemon, I am deeply concerned about what appears to be a tremendous failure by the Board to competently plan for the future and manage an effective succession process. This latest failure in my opinion only amplifies the urgency the Company faces and the obvious need for the CEO search to be led by new, independent directors with real experience. I believe that the Board should seek the advice of individuals with specific and unique expertise, and deep knowledge of the Company, to advise on the CEO selection process."
Wilson continued, "The Board's praise for
Media Contacts:
View original content:https://www.prnewswire.com/news-releases/chip-wilson-comments-on-leadership-change-at-lululemon-302640131.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026
- Chainlink Price Prediction: Archax Picks LINK Data Streams as Remittix Earn Readies Morpho, Fluid and Maple Finance Pools
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share